Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple conversation prevent deadly blood clots?

NCT ID NCT06731244

Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a shared decision-making process, which uses personalized risk scores, can help patients with unprovoked blood clots choose the best duration of blood-thinning medication. The goal is to reduce the chance of another clot or serious bleeding while improving patient satisfaction. About 2,400 adults who have had a first unprovoked clot will be randomly assigned to usual care or the shared decision-making approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
shared decision-making process
What this could lead to
If successful, this approach could help patients and doctors choose the right duration of blood-thinning therapy, reducing the risk of another clot or serious bleeding.
What could go wrong
This is a large but early-stage study testing a decision-making process, not a drug. The results may not change current practice if the intervention does not clearly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient \> or = 18 years, * Patient with a first episode of symptomatic unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT) treated for 3 to 6 uninterrupted months with full dose anticoagulant therapy, * Signed informed consent. Exclusion Criteria: * Unable or refusal to give informed consent, * Isolated distal DVT, * Isolated sub-segmental PE * Previous unprovoked VTE * Known CTEPH * Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation, mechanic valves…), * Interruption of anticoagulation for 14 days or more before the inclusion, * Active cancer of less than 24 months, * Current pregnancy, * Life expectancy \<18 months (e.g.; patients with an end-stage chronic disease) * Not affiliated to national insurance, social security (only for France)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM - Hôpital la Timone

    NOT_YET_RECRUITING

    Marseille, 13005, France

  • APHP-Colombes

    NOT_YET_RECRUITING

    Colombes, 92700, France

  • Aphp-Hegp

    NOT_YET_RECRUITING

    Paris, 75015, France

  • Aphp-Hegp

    NOT_YET_RECRUITING

    Paris, 75015, France

  • CH Le Mans

    NOT_YET_RECRUITING

    Le Mans, 72037, France

  • CHU Brest

    RECRUITING

    Brest, France, 29609, France

  • CHU Saint Etienne

    NOT_YET_RECRUITING

    Saint-Etienne, 42270 Saint Priest En Jarez, France

  • CHU d'Amiens - Picardie

    NOT_YET_RECRUITING

    Amiens, 80054, France

  • CHU d'Angers

    NOT_YET_RECRUITING

    Angers, 49933, France

  • CHU de Clermont Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU de Dijon - Hôpital François Mitterand

    NOT_YET_RECRUITING

    Dijon, 21079, France

  • CHU de Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34295, France

  • CHU de Nancy

    NOT_YET_RECRUITING

    Nancy, 54511, France

  • CHU de Nantes

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • CHU de Nîmes

    NOT_YET_RECRUITING

    Nîmes, 30029, France

  • CHU de Rennes

    NOT_YET_RECRUITING

    Rennes, 35200, France

  • CHU de Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67091, France

  • CHU de Toulouse

    NOT_YET_RECRUITING

    Toulouse, 31000, France

  • HCL - Hôpital Edouard Herriot

    NOT_YET_RECRUITING

    Lyon, 69003, France

  • Hôpital National d'Instruction des Armées Percy

    NOT_YET_RECRUITING

    Clamart, 92140, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.